Healthcare innovation and compliance: why leaders need both

A strong compliance mindset is vital for moving healthcare innovation from promising idea to investable, market-ready proposition.

Digital health, AI-enabled care, and personalised treatments present key growth opportunities, but they also make regulation and trust an even greater necessity. As connected devices and adaptive software become more common across the patient journey, healthcare and life sciences organisations will need to show that innovation is not only effective and commercially viable, but also responsible and compliant. 

Investor confidence and market access depend on it.

For scaling healthcare businesses without the specialist knowledge or capital of bigger industry players, compliance can feel like a barrier to progress. When considered too late, it risks launch delays, increased costs, and weakened trust. 
But when built in early, it supports faster decisions and more resilient growth.

SMEs drive innovation, but compliance resources are stretched

The UK and U.S. life sciences markets both demonstrate how the sector’s innovation is driven by businesses with fewer compliance-focused resources than their larger peers.

The UK life sciences industry is growing rapidly. The latest estimates show turnover increased from £108.1 billion in 2021/22 to £146.9 billion in 2023/24, while small and medium-sized enterprises (SMEs) account for 94% of UK life sciences companies. In the U.S., a similar scenario is visible on a larger scale. 

CBRE’s 2026 U.S. Life Sciences Trends report points to renewed activity in the market, with facility investment seeing a historic high. In 2025, AI-related venture capital investment in life sciences also reached a record 400 deals, underscoring the role of emerging growth businesses in advancing innovation.

Renewed market activity, however, does not remove the constraints facing these businesses. They remain more exposed to tighter capital conditions, slower IPO markets, and higher evidence expectations as they move from development to commercialisation.

What’s more, the pressure of these evidence expectations will be compounded by the need to prove AI and connected technologies are effective and trustworthy.

How regulators are engaging with AI and connected technologies

Recent signals in the UK and U.S. indicate that regulators are making compliance more navigable for innovative businesses, without lowering expectations for evidence and accountability. 

In its latest performance update, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) said it had met or exceeded its legal deadlines for key decisions across licensing, clinical trials, and safety. When healthcare organisations are ready with the right evidence, documentation, and controls, a faster and more predictable regulator supports innovation.

Regulatory shifts in the U.S. point to a more explicit and technical compliance environment. The Food and Drug Administration’s (FDA’s) 2025 draft guidance on AI-enabled devices sets clearer expectations across the full product lifecycle. This includes data quality, bias management, transparency, documentation, post-market monitoring, and change management for software updates. 

Additionally, the FDA’s 2026 announcement on drug approvals suggests a similar move towards more targeted but evidence-heavy regulatory expectations: one adequate, well-controlled pivotal trial, supported by confirmatory evidence, is now the default option for many approvals. This change may place greater weight on the quality, coherence, and credibility of the evidence package.

Proposed updates to the HIPAA Security Rule and the ONC HTI-1 final rule show that expectations are also rising around health data protection, transparency, and the use of algorithm-enabled health IT.

For healthcare and life sciences leaders, these developments mean compliance must be embedded continuously across product design, data governance, clinical evidence strategy, and commercial credibility.

Reframe compliance as a growth capability

The strongest organisations do not treat compliance as a gateway at the end of development, but use it as a design principle from the beginning.

Early regulatory thinking helps organisations decide what evidence to generate, which markets to prioritise, which claims they can support, what data they need, and which controls will stand up to scrutiny. It also creates stronger conversations with investors, partners, buyers, and international stakeholders.

Taking this approach aligns with the wider move towards agile, risk-based regulation. The OECD Regulatory Policy Outlook 2025 argues for regulation that supports innovation while managing emerging harms. Its focus on anticipatory governance, ongoing review, stakeholder engagement, and future-ready institutions is highly relevant to healthcare and life sciences. By building regulatory thinking into their strategy from the outset, healthcare organisations can move with greater confidence as technologies and expectations evolve. 

Rather than being a barrier to progress, compliance becomes part of the structure that allows ambition to scale.

How to build regulatory strategy into the growth plan

A strong regulatory strategy connects healthcare innovation, risk, evidence, and commercial planning. It gives leaders a clear view of what must be true for a product or service to reach the market and grow.

For digital health and AI products, intended use drives many regulatory questions. It affects whether a product may fall within medical device regulation, what evidence is needed, and how safety and performance should be monitored.

To reduce regulatory risk later, executive teams can take several actions early in the product development process:

• Define how the product will be used, including whether it supports clinical decision-making, diagnosis, treatment, monitoring, or workflow. 
• Identify who will rely on the product, such as clinicians, patients, providers, payers, or operational teams. 
• Clarify the claims the organisation intends to make, as these can affect regulatory classification and commercial positioning. 
• Assess the regulatory pathway early based on the product’s intended use, users, claims, and risk profile. 
• Understand the consequences of failure, including what happens if the product fails, drifts, or produces an incorrect result.

These questions should sit at the heart of growth planning. Future-ready organisations must also have plans for continuous evidence generation, accountability for data, and active oversight of AI-enabled tools.

The leading healthcare and life sciences businesses will be the ones connecting regulatory strategy and innovation planning from the start. As regulators sharpen expectations around evidence, AI, and data protection, early compliance thinking will help organisations build trust and reduce risk as they innovate. 

This is where compliance readiness and scalable growth come together for the healthcare and life sciences industry.

Contact us

Complete this form and an RSM representative will be in touch.